CSF3 and Miyoshi myopathy: These data demonstrated numerically higher average levels of EGF-, TNF-α/NFκB- and HBO1-related gene expression with the use of the long-acting CXCR4i motixafortide as compared with short-acting CXCR4i with plerixafor or G-CSF alone, within most HSC1–6 and MLP subsets in healthy allo-donors, whereas the differences in gene expression scores for EGF-, TNF-α/NFκB- and HBO1-related genes in HSC1–6 and MLP subsets in the MM cohorts were relatively similar across mobilization regimens.